Forest Hills Dermatology Group

Forest Hills, New York 11395

0 studies enrolling now · 14 studies all time

What they study most

Alopecia Areata, Atopic Dermatitis, Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Non-segmental Vitiligo, Onychomycosis, Plaque Psoriasis, Plaque Type Psoriasis, Psoriasis, Psoriatic Arthritis, Skin Diseases, Submental Fullness

Studies at this site

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC — Running, not enrolling
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) — Completed
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis — Completed
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis — Completed
Study of Ruxolitinib Cream in Children With Atopic Dermatitis — Completed
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Completed
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis — Completed
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis — Stopped early
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail — Completed
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp — Completed
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis — Completed
Condition of Submental Fullness and Treatment Outcomes Registry — Completed
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira — Completed